Sinovac Biotech Ltd. annual net income 2016-2022
Sinovac Biotech Ltd., one of China's leading vaccine producers, reported an annual net income of more than 14 billion U.S. dollars in 2021. The company enjoyed massive growth in its financial figures since the start of the COVID-19 pandemic, thanks to the global demands of CoronaVac, Sinovac's COVID-19 vaccine. Unlike Sinopharm, all of Sinovac's revenues are generated from the sales of vaccine products. Therefore, the future prospect of the company's further development after the COVID-19 pandemic remains unclear.